Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 693700398271--
Entreprise Value (EV)1 693650345227148217
P/E ratio -8,97x-6,52x-3,05x-2,49x-3,63x-5,88x
Yield ------
Capitalization / Revenue 615x38 894x33,7x5,62x2,87x2,10x
EV / Revenue 615x36 133x29,3x4,71x1,57x1,68x
EV / EBITDA -9,03x-5,96x-2,73x-2,51x-1,75x-2,61x
Price to Book -3,89x4,07x---
Nbr of stocks (in thousands) 16 10220 98022 09322 420--
Reference price (USD) 43,133,418,012,112,112,1
Announcement Date 02/28/201903/02/202003/18/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 1,130,0211,848,294,4129
EBITDA1 -76,8-109-126-90,2-84,7-83,1
Operating profit (EBIT)1 -77,2-109-127-97,9-78,0-51,6
Operating Margin -6 842%-608 211%-1 074%-203%-82,6%-39,9%
Pre-Tax Profit (EBT)1 -75,5-105-125-110-79,3-53,0
Net income1 -75,7-105-128-110-80,7-54,5
Net margin -6 707%-584 144%-1 089%-227%-85,5%-42,1%
EPS2 -4,80-5,12-5,90-4,86-3,33-2,06
Dividend per Share2 ------
Announcement Date 02/28/201903/02/202003/18/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 7,4913,011,416,718,521,8
EBITDA ------
Operating profit (EBIT)1 -26,1-22,8-23,4-22,6-25,8-23,2
Operating Margin -349%-175%-207%-136%-139%-106%
Pre-Tax Profit (EBT)1 -25,9-25,9-30,2-29,2-22,4-17,4
Net income1 -25,9-26,2-30,2-28,0-22,9-19,8
Net margin -346%-201%-266%-168%-123%-90,8%
EPS2 -1,17-1,17-1,35-1,22-1,06-0,93
Dividend per Share ------
Announcement Date 05/13/202108/04/202111/15/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 -49,752,944,112354,2
Leverage (Debt / EBITDA) -0,46x0,42x0,49x1,45x0,65x
Free Cash Flow1 -37,9-71,3-107-86,0-33,0-2,00
ROE (Net Profit / Equities) --77,8%-92,9%---
Shareholders' equity1 -135138---
ROA (Net Profit / Asset) --68,7%-79,2%---
Assets1 -153162---
Book Value Per Share -8,584,42---
Cash Flow per Share ------
Capex 0,560,331,22---
Capex / Sales 49,6%1 806%10,3%---
Announcement Date 02/28/201903/02/202003/18/2021---
1 USD in Million
Key data
Capitalization (USD) 271 061 729
Net sales (USD) 11 799 000
Number of employees 198
Sales / Employee (USD) 59 591
Free-Float 91,4%
Free-Float capitalization (USD) 247 755 836
Avg. Exchange 20 sessions (USD) 2 063 484
Average Daily Capital Traded 0,76%
EPS & Dividend